Early-stage Ion Channel Programs

About Autifony Therapeutics

Autifony Therapeutics is a private, clinical-stage biotech founded in 2011 as a spin-out from GlaxoSmithKline. The company's core expertise lies in translating ion channel biology into therapeutics, with two clinical-stage Kv3 modulators for Fragile X syndrome (AUT00206, with FDA Orphan Drug Designation) and rare myoclonic epilepsies (AUT00201). Beyond these lead rare disease programs, Autifony has built a broader preclinical and early-stage pipeline targeting other CNS disorders, positioning it as a specialist in neuronal excitability and hearing disorders.

Therapeutic Areas